Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurochem Int ; 149: 105108, 2021 10.
Article in English | MEDLINE | ID: mdl-34175350

ABSTRACT

Pseudoginsenoside-F11 (PF11), an ocotillol-type ginsenoside, has been reported to exert neuroprotective effects on ischemic stroke induced by permanent and transient middle cerebral artery occlusion in experimental animals. The aim of the present study was to investigate the effect of PF11 on thromboembolic stroke in rats and its possible mechanisms on thromboinflammation. PF11 (4, 12, 36 mg/kg) was injected intravenously (i.v.) once a day for 3 consecutive days to male Wistar rats followed by embolic middle cerebral artery occlusion (eMCAO). The results showed that PF11 significantly reduced the cerebral infarction volume, brain edema and neurological deficits induced by eMCAO. Meanwhile, the thromboinflammation in the ischemic hemisphere was observed at 24 h after eMCAO, as indicated by the increased number of microvascular thrombus and inflammatory response. Moreover, eMCAO resulted in the up-regulation of platelet glycoprotein Ibα (GPIbα) and VI (GPVI), as well as the activation of contact-kinin pathway. Notably, PF11 significantly reversed all these changes. Furthermore, PF11 prevented the eMCAO-induced loss of tight junction proteins and up-regulation of matrix metalloproteinase-9 (MMP-9), thus leading to the alleviation of blood-brain barrier (BBB) damage. In conclusion, the present study revealed that thromboinflammation was induced in the ischemic hemisphere of rats after eMCAO and PF11 exerted marked protective effects against thromboembolic stroke by attenuating thromboinflammation and preventing BBB damage. This research further identifies the potential therapeutic role of PF11 for ischemic stroke.


Subject(s)
Ginsenosides/therapeutic use , Inflammation Mediators/antagonists & inhibitors , Stroke/drug therapy , Thromboembolism/drug therapy , Thromboinflammation/drug therapy , Animals , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/pathology , Cerebrovascular Circulation/drug effects , Cerebrovascular Circulation/physiology , Ginsenosides/pharmacology , Inflammation Mediators/metabolism , Male , Rats , Rats, Wistar , Stroke/metabolism , Stroke/pathology , Thromboembolism/metabolism , Thromboembolism/pathology , Thromboinflammation/metabolism , Thromboinflammation/pathology
2.
Thromb Haemost ; 121(9): 1138-1150, 2021 09.
Article in English | MEDLINE | ID: mdl-33352593

ABSTRACT

The new concept of thrombosis associated with an inflammatory process is called thromboinflammation. Indeed, both thrombosis and inflammation interplay one with the other in a feed forward manner amplifying the whole process. This pathological reaction in response to a wide variety of sterile or non-sterile stimuli eventually causes acute organ damage. In this context, neutrophils, mainly involved in eliminating pathogens as an early barrier to infection, form neutrophil extracellular traps (NETs) that are antimicrobial structures responsible of deleterious side effects such as thrombotic complications. Although NETosis mechanisms are being unraveled, there are still many regulatory elements that have to be discovered. Micro-ribonucleic acids (miRNAs) are important modulators of gene expression implicated in human pathophysiology almost two decades ago. Among the different miRNAs implicated in inflammation, miR-146a is of special interest because: (1) it regulates among others, Toll-like receptors/nuclear factor-κB axis which is of paramount importance in inflammatory processes, (2) it regulates the formation of NETs by modifying their aging phenotype, and (3) it has expression levels that may decrease among individuals up to 50%, controlled in part by the presence of several polymorphisms. In this article, we will review the main characteristics of miR-146a biology. In addition, we will detail how miR-146a is implicated in the development of two paradigmatic diseases in which thrombosis and inflammation interact, cardiovascular diseases and sepsis, and their association with the presence of miR-146a polymorphisms and the use of miR-146a as a marker of cardiovascular diseases and sepsis.


Subject(s)
Cardiovascular Diseases/metabolism , Extracellular Traps/metabolism , MicroRNAs/metabolism , Neutrophils/metabolism , Sepsis/metabolism , Thromboinflammation/metabolism , Animals , Blood Coagulation , Cardiovascular Diseases/blood , Cardiovascular Diseases/genetics , Endothelial Cells/metabolism , Extracellular Traps/genetics , Humans , MicroRNAs/genetics , Polymorphism, Genetic , Sepsis/blood , Sepsis/genetics , Thromboinflammation/blood , Thromboinflammation/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...